The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
There is an urgent medical need to evaluate new safe and effective treatment approaches for gastrointestinal graft-versus-host disease (GI GvHD) dependent or refractory to steroid treatment. To date, acute GI GvHD is still considered one of the major causes of mortality for patients who undergo an allogeneic hematopoietic stem cell transplant (allo-HSCT).1
The critical role of gut microbiota in GI GvHD and the potential of donor fecal microbiota transplantation (FMT) has been previously suggested based on clinical data. However, the high risk of infection in these immunocompromised patients, and the possibility of transferring multidrug-resistant organisms to them, has obstructed advances in the field.
Yannouck F. van Lier and colleagues from Amsterdam UMC recently published their experience in the journal Science Translational Medicine, and here we provide a summary of their findings.1
This is a single-center, single-arm trial to evaluate the efficacy and safety of a single administration of donor FMT via nasoduodenal infusion in adult patients who underwent allo-HSCT and experienced steroid-dependent or steroid-refractory intestinal GvHD (FARAH study, ISRCTN14530574). All patients received a bowel lavage 2 hours before donor FMT, in order to give the transplanted microbiota space to engraft.
A total of 15 patients were enrolled and evaluable for treatment response. Baseline characteristics (at the time of donor FMT) can be found in Table 1.
Table 1. Baseline characteristics1
Characteristics at baseline |
Value (N = 15) |
*cyclosporin, mycophenolate mofetil, methotrexate, ruxolitinib, sirolimus, or tacrolimus. |
|
Median age (range), years |
57 (20–72) |
FMT indication |
|
Steroid-refractory |
6 |
Steroid dependent |
9 |
Diagnosis |
|
Acute myeloid leukemia |
8 |
Myelodysplastic syndrome |
3 |
Myeloproliferative disorder (MF) |
2 |
Lymphoma |
2 |
Conditioning regimen received |
|
Reduced-intensity |
12 |
Myeloablative |
3 |
|
|
I |
7 |
II |
3 |
III |
3 |
IV |
2 |
Additional treatment to systemic steroids |
|
Local therapy (budesonide) |
8 |
Systemic therapy* |
12 |
GvHD involvement of other organs |
|
Skin |
3 |
Liver |
1 |
The procedure was considered safe for all participants due to a low incidence of adverse events, and all infections reported being considered not related to the FMT.
Overall, ten of 15 patients were in CR at 4 weeks after donor FMT, showing improved GvHD symptoms during the first and second week after the procedure. Successful immunosuppressant tapering was possible in six patients. Find a summary of treatment responses in Table 2.
Table 2. Summary of donor FMT response1
Response |
Number of patients |
*All patients received antibiotic therapy after donor FMT, in addition to the prophylactic treatment. |
|
CR at 4 weeks |
10 |
CR of steroid-refractory GI GvHD |
3 |
CR of steroid dependent GI GvHD |
7 |
CR with secondary failure at 24 weeks |
4* |
Partial response |
0 |
Non-responders |
5 |
Died during follow-up |
4† |
The investigators reported that patients with higher gut microbial diversity at baseline were more likely to obtain a CR following FMT. Patients who responded to treatment showed a progressive improvement in microbiota composition which developed similarities to the donor sample. This change was directly associated with a decrease in diarrhea episodes.
Moreover, data suggest that higher diversity might not be the only factor influencing response, as also the presence of some specific bacterial species was linked with better outcomes.
Finally, the authors identified fucosyltransferase 2 (FUT2) secretor status as an additional prognostic factor for response. FUT2 is an enzyme found in the gastrointestinal epithelium crucial for the secretion of ABO blood group antigens into the gut lumen, where it constitutes a significant source of carbohydrates for the microbiota potentially improving engraftment of the donor fecal microbiota and maintaining its diversity. In this study, eight patients with a CR were considered FUT2 secretors (as detected by epithelial staining in gut biopsies); while two out of four non-responders presented with a non-secretory phenotype.
In line with previously published reports, the FARAH study results show the promising potential of donor FMT to improve acute GI GvHD safely and rapidly in a significant proportion of patients with steroid-refractory or dependent disease. However, these findings need to be confirmed in a larger clinical trial.
Additionally, the future implementation of donor FMT will also need to be accompanied by a better understanding of factors influencing engraftments, new approaches to enhance microbiota diversity, and tools to identify those patients who will benefit the most from this procedure.
Some questions remain unanswered and could also be addressed in future studies:
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content